BDAZ - I'm very happy to see your comments  about the % RRR. It has been my understanding from day one that for a CVOT trial with this few patients that they would need a minimum of 30% RRR in order to have the statistical significance necessary for the payors to be satisfied paying for the drug. If 30% RRR was not achieved then it would be necessary to add 1200 more patients to the trial, achieve 375 three point MACE and have a minimum of 25% RRR to meet minimum statistical requirements necessary with that now larger trial size.

I must say that the company seems to be doing everything possible to meet the highest RRR they can given the parameters they have to work with. Dosing right up to 250 events and ending up with around 270 events I understand will be better for them than having just 250 events. By not having an SSRA they forgo the statistical penalty of 1% to 2% which is also in their favor. No matter how small that advantage is, it is still an advantage. Frankly I think they are setting it up to knock it out of the park on every front. 

Exciting times ahead.

tada